Ron Behling
About Ron Behling
Ron Behling is the Director of Pharmaceutical Development Informatics at Bristol-Myers Squibb, with a background in informatics and predictive sciences and a strong interest in leveraging data analytics for precision medicine.
Company
Ron Behling is currently employed at Bristol-Myers Squibb, where he serves as the Director of Pharmaceutical Development Informatics. His history with the company spans over three decades, having previously held the position of Director of Exploratory Development Informatics from 1988 to 2007.
Title
As the Director of Pharmaceutical Development Informatics at Bristol-Myers Squibb, Ron Behling oversees the design and implementation of informatics systems that drive the pharmaceutical development processes. His role involves strategic leadership and oversight in integrating data analytics to enhance drug development and patient outcomes.
Education and Expertise
Ron Behling holds a PhD and a strong educational background rooted in Chemistry, having studied at UC San Diego from 1979 to 1986. Prior to that, he attended the University of Chicago from 1975 to 1979. His expertise spans pharmaceutical development informatics, predictive sciences, and data analytics with a focus on precision medicine.
Background
Ron Behling's career at Bristol-Myers Squibb includes significant roles such as leading the process integration for the new Biologics Process and Product Development (BPPD) organization. He has experience in managing clinical trial designs, optimizing drug development processes, and informatics integration for newly acquired companies like Medarex.
Achievements
Ron is a certified Kaizen Leader who has led projects generating a 15% productivity improvement in the Drug Safety Evaluation Division, resulting in $20 million annual operations savings. His contributions include developing digital health solutions for enhanced patient care, leveraging translational medicine, and working on initiatives to improve health equity and access to care for underserved patients.